Dr. Thomas S. Wilson

Since joining Kirkland, Thomas’ representative matters have included:

• Advising KKR on its investment in Avantus.
• Advising Nordic Capital on a joint venture with Ontario Teachers’ Pension Plan Board to invest in Advanz Pharma.
• Advising Digital 9 Infrastructure on the sale of Verne Global.
• Advising KKR and GED Capital on the acquisition of Eugin Group.
• Advising SK Capital Partners and its portfolio company, IPACKCHEM, a provider of jerrycans and plastic containers, in its $538 million sale to Greif (NYSE: GEF).
• Advising Gamut Capital and its portfolio company, Davis-Standard, in its acquisition of the Extrusion Technology Group, a provider of extrusion equipment and services, from Nimbus.
• Advising Eli Lilly and Company (NYSE: LLY) in its $1.4 billion acquisition of POINT Biopharma (NASDAQ: PNT), a radiopharmaceutical company.
• Advising Sun Capital on the acquisition of Koch Separation Solutions from Koch Industries.
• Advising Stellant on the acquisition of Power Systems Technology Product Line from Comtech.
• Advising Venator to emerge from Chapter 11 restructuring.
• Advising Brightstar Capital Partners on its acquisition of Ausenco.
• Advising Eli Lilly and Company (NYSE: LLY) in its $1.925 billion acquisition of Versanis Bio, a clinical-stage biopharmaceutical company.
• Advising BAE Systems (LSE: BA) in its $5.5 billion acquisition of Ball Corp.'s (NYSE: BALL) defense and commercial space unit Ball Aerospace.
• Advising Union Park Capital on its sale of Process Insights.
• Advising SourceCode and Cerberus on its agreement to acquire Boston Limited.
• Advising KKR in its $1.3 billion acquisition of Chase Corporation.
• Advising Nordic Capital on the sale of Bladt Industries to CS Wind.
• Advising CyrusOne to form joint venture with KEPCO.
• Advising Eli Lilly on the acquisition of DICE Therapeutics.
• Advising Metaco on its sale to Ripple.
• Advising Nordic-backed ArisGlobal on the acquisition of Amplexor Life Sciences.
• Advising Charlesbank Capital Partners on its acquisition of Maltego Technologies GmbH.
• Advising Eli Lilly on its divesture of BAQSIMI to Amphastar.
• Advising Nordic Capital on the acquisition of a majority stake in corpuls.
• Advising Wendel on exclusive negotiations relating to the acquisition of Scalian Group.
• Advising Mohari Hospitality in the acquisition of Tao Group Hospitality.
• Advising Groupe Bruxelles Lambert in the agreement to combine Webhelp and Concentrix Corporation.
• Advising Ares Management and WHP Global on Ares’ $375 million equity investment in WHP Global.
• Advising Waters Corporation on the acquisition of Wyatt Technology.
• Advising Linden Capital Partners on the acquisition of LifeStyles Healthcare.
• Advising Resonetics on its $900 million acquisition of SAES Medical Nitinol Business.
• Advising Platinum Equity on its agreement to acquire HarbisonWalker International.
• Advising Providence Equity Partners on investment in A2MAC1, a leading provider of vehicle benchmarking insights and solutions across the mobility industry.
• Advising SK Capital Partners on its agreement to acquire Apotex Pharmaceutical Holdings Inc.
• Advising CPP Investments on the acquisition of a stake in Universal Investment.
• Advising Platinum Equity on the acquisition of High Temperature Solutions Business.
• Advising Hellman & Friedman on the $10.2 billion acquisition of Zendesk by an investor group.
• Advising Oakley Capital and other principal sellers on the sale of Contabo to KKR.
• Advising KKR and Bettcher Industries on the acquisition of Frontmatec from Axcel.
• Advising KKR on its investment in Apexanalytix. 
• Advising UserZoom, a portfolio company of Thoma Bravo, on the acquisition of Testapic. 
• Advising GBL on the acquisition of Sanoptis.
• Advising GBL on the acquisition of Affidea.
• Advising Turn/River Capital on its $570 million acquisition of Tufin. 
• Advising a potential purchaser in relation to certain divestment businesses in the $44 billion S&P Global/IHS Markit case which was conditionally cleared by the EU Commission following a Phase II review. 
• Advising Brookfield on the voluntary public takeover offer for alstria office REIT-AG. 
• Advising Engineered Controls, a portfolio company of Windjammer Capital Investors, on its $631 million acquisition by Dover Corporation. 
• Advising Inmarsat and its controlling consortium on the $7.3 billion combination with Viasat, Inc.
• Advising Silver Lake on the $555 million funding round to power the accelerated growth of Mirakl.
• Advising Guidepost Growth Equity on its lead role in a $150 million round of funding for Atheneum.
• Advising Silversmith Capital and DistroKid on a substantial investment from Insight Partners, valuing DistroKid at $1.3 billion.
• Advising Celanese Corporation on the $1.15 billion acquisition of ExxonMobil’s Santoprene TPV elastomers business.
• Advising Bain Capital on the bidding process for a majority stake in Condor.
• Advising SK Capital on the c. $2 billion sale of Perimeter Solutions to EverArc Holdings Ltd. 
• Advising SK Capital on the formation of a consortium with Heubach Group and the subsequent acquisition of Clariant's Pigments business. 
• Advising Donuts, Inc. on its sale to Ethos Capital. 
• Advising Cerberus and Koch on their agreement to acquire the PQ Performance Chemicals business of PQ Group Holdings Inc. for approximately $1.1 billion. 
• Advising Madison Dearborn Partners and its portfolio company Performance Health on the sale of its Biofreeze brand to Reckitt Benckiser Group.
• Advising Core Equity Holdings on various transactions, including the bidding processes for ADCO Group and Canyon Bicycles.  
• Advising Donuts Inc. on its acquisition of Afilias, Inc. 
• Advising LyondellBasell on its definitive agreement with Sasol to form a 50/50 polyethylene joint venture through which LyondellBasell acquired 50% of select assets in Louisiana for a total consideration of $2 billion.
• Advising SK Capital on its acquisition of a stake in Venator Materials PLC from Huntsman Corporation.
• Advising Arya Sciences Acquisition Corp. II on its $1.3 billion combination with Cerevel Therapeutics.
• Advising Vitruvian Partners on its sale of Technogroup to 3i-backed Evernex.
• Advising Arya Sciences Acquisition Corp. on its combination with Immatics Biotechnologies.
• Advising AbbVie on its $63 billion acquisition of Allergan.
• Advising GlaxoSmithKline on its $12.7 billion joint venture with Pfizer to combine their consumer health businesses (German and Austrian filing only).
• Advising the DCSA container liner shipping initiative on competition compliance aspects.
• Advising the ad hoc group of bondholders of the Lebara Group on its restructuring.
• Advising Aptiv on its acquisition of gabo Systemtechnik GmbH from Bregal Unternehmerkapital.
• Advising a consortium of lenders including Blantyre on the restructuring of Bulsatcom EAD.
• Advising KKR on its acquisition of Corel Corporation, one of the world’s top software platforms.
• Advising Droga5, one of the world’s most innovative and influential creative agencies, on its acquisition by Accenture.
• Advising Searchlight Capital on the acquisition of a 26% minority stake in Latécoère, a French aeronautics company.

Prior to joining Kirkland, Thomas’ representative matters included:

• Advising Siemens on the proposed combination of Siemens’ and Alstom’s mobility businesses.
• Advising BASF on competition law aspects regarding the combination of Wintershall and DEA oil & gas businesses generating combined revenues of €4.7 billion.
• Advising a chemicals company on an EU cartel investigation and various compliance aspects, including a company audit.
• Advising Maersk Line on the global coordination, across more than 15 jurisdictions, of its acquisition of Hamburg Süd, which also involved successful Phase I remedy negotiations with the European Commission.
• Advising Alere Inc on the EU competition law aspects of its $5.8 billion acquisition by Abbott Laboratories.
• Advising CK Hutchison (owner of the “3” Group of mobile network operators) on the €20 billion combination of its Italian mobile business with Wind Italy to create the largest mobile operator in Italy.
• Advising Rexam on the global merger control aspects of its £4.3 billion public bid by US rival Ball, bringing together the world’s two largest drinks cans producers.
• Advising Amadeus before the Bundeskartellamt on the acquisition of corporate travel technology company i:FAO.
• Advising Hapag-Lloyd on the merger control aspects of its merger with the container shipping activities of Chile's Compañía Sud Americana de Vapores.
• Advising ED&F MAN on its sale of a controlling stake to Südzucker – the sugar industry transaction prompted an in-depth review by the EU Commission and the negotiation of a complex remedy package in order to achieve Phase II clearance.
• Advising Synthes, the Swiss medical device manufacturer, on merger control and antitrust aspects in Europe and Asia of its acquisition by Johnson & Johnson in a deal valued at $21 billion.
• Advising One Equity Partners on antitrust aspects of its acquisition of a majority participation in Constantia Packaging.
• Advising Deutsche Bahn on the merger control aspects of its £1.6 billion public bid for Arriva, including the negotiation of complex remedies in order to secure Phase I clearance from the EU Commission.
• Advising BASF in its successful appeal before the European General Court challenging the European Commission’s cartel fining decision in relation to its investigation into the heat stabilisers sector.
• Advising the State of Nordrhein-Westfalen on the State aid and competition law aspects of the implementation of WestLB's restructuring plan and on the creation of the first 'bad bank' under German financial stability rules.
• Advising BASF on competition law aspects of its $3 billion acquisition of Swiss chemicals producer Ciba.

Freshfields Bruckhaus Deringer LLP, Brussels

• Counsel (2008–2018)